Elite Pharmaceuticals, Inc. News Releases

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information

Thu, 13 Aug 2026 16:11:00 -0400

Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter").Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or...

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026

Mon, 10 Aug 2026 16:54:00 -0400

Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026 Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2027 fiscal year will be released on Thursday, August 13, 2026. Elite's management will host a live conference call on...

Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL

Tue, 04 Aug 2026 07:00:00 -0400

Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat Parkinson's...

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information

Mon, 29 Jun 2026 16:29:00 -0400

Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026").Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior...

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026

Tue, 23 Jun 2026 07:00:00 -0400

Financials for Fiscal Year 2026 Ended March 31, 2026 will be released on Monday, June 29, 2026 Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2026 year-end financial results on Monday, June 29, 2026. Elite's management will host a live conference call on Tuesday, June 30th, at 11:30 AM EDT to discuss the...

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Mon, 15 Jun 2026 07:00:00 -0400

Northvale, New Jersey--(Newsfile Corp. - June 15, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product. IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million. The studies conducted...

Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product

Mon, 01 Jun 2026 07:00:00 -0400

Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic drug product in the class of medications called anticoagulants.IQVIA reported branded product sales for the...

Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets

Thu, 02 Apr 2026 08:00:00 -0400

Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methadone tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative options...

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information

Tue, 17 Feb 2026 16:19:00 -0500

Conference Call Scheduled for Wednesday, February 18 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter").Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of...

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026

Wed, 11 Feb 2026 16:30:00 -0500

Financials for Third Quarter of Fiscal Year 2026 Ended December 31, 2025 will be released on Tuesday, February 17, 2026 Northvale, New Jersey--(Newsfile Corp. - February 11, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026. Elite's management will host a live conference...